Sign inJoin waitlistJoin the waitlist

Michael Migden

, Program Director · University of Texas M D Anderson Cancer Center

Credentials: · · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2005–2006
University of Texas M D Anderson Cancer Center
2004–2005
Mayo Clinic
2001–2004
Dermatology
Mayo Clinic
1998–2001
Micrographic Surgery and Dermatologic Oncology
2000–2001
Preliminary Internal Medicine
Mayo Clinic
1997–1998
University of Utah School of Medicine
1993–1997

Research

Efficacy and safety of vismodegib in advanced basal-cell carcinoma
New England Journal of Medicine · 2012 · 1,139 citations
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
New England Journal of Medicine · 2018 · First of 37 authors · 1,114 citations
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial
The Lancet Oncology · 2020 · First of 22 authors · Corresponding · 412 citations

Sirunya Silapunt
23 papers
Anne Chang
17 papers · 1 as a fellow
KL
Karl Lewis
15 papers
Moran Amit
12 papers · 4 as a resident
IL
Israel Lowy
10 papers
Jeffrey Myers
10 papers
MF
Matthew Fury
10 papers
PN
Priyadharsini Nagarajan
10 papers · 1 as a fellow
Neil Gross
9 papers
NK
Nikhil Khushalani
9 papers
AS
Aleksandar Sekulic
8 papers
NA
Nader Aboul-Fettouh
7 papers · 7 as a resident

Clinical trials

Spectral Diagnosis of Cutaneous Malignancy
Principal investigator · Completed
M.D. Anderson Cancer Center
2007–2018
L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
Site PI · Recruiting · Phase 2
Philogen S.p.A.
2026–2031
L19IL2/TNF in Patients With Basal Cell Carcinoma
Site PI · Recruiting · Phase 2
Philogen S.p.A.
2026–2031
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
Site PI · Recruiting · Phase 2
Philogen S.p.A.
2026–2031